Colorectal Cancer Clinical Trial
Official title:
A Pharmacogenetic-Based Phase I Trial of Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in Patients With Advanced Gastrointestinal Cancer
Verified date | September 2016 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill
more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when
given together with fluorouracil and leucovorin in treating patients with advanced
gastrointestinal cancer.
Status | Completed |
Enrollment | 7 |
Est. completion date | December 3, 2012 |
Est. primary completion date | November 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Biopsy confirmed diagnosis of gastrointestinal cancer - Advanced, unresectable disease - Confirmation of UGT1A1 TA indel genotype - Measurable or evaluable (non-measurable) disease - Measurable disease is defined as = 1 lesion that can be accurately measured (longest diameter to be recorded) as = 2.0 cm with conventional techniques or as = 1.0 cm with spiral CT scan - Clinical lesions will only be considered measurable when they are superficial (e.g., skin nodules, palpable lymph nodes) - Lesions on chest x-ray are acceptable as measurable lesions when they are clearly defined and surrounded by aerated lung - The following are considered non-measurable disease: - Bone lesions - Leptomeningeal disease - Ascites - Pleural/pericardial effusions - Lymphangitis cutis/ pulmonis - Inflammatory breast disease - Abdominal masses (not followed by CR scan or MRI) - Cystic lesions - All other lesions (or sites of disease), including small lesions (longest diameter < 2.0 cm with conventional techniques or as < 1.0 cm with spiral CT) - No known central nervous system metastases or carcinomatous meningitis PATIENT CHARACTERISTICS: Inclusion criteria - Life expectancy = 12 weeks. - ECOG performance status 0-2 - ANC = 1,500/mm³ - Platelet count = 100,000/mm³ - SGOT = 2.5 times upper limit of normal (ULN) (= 5 times ULN if liver metastases) - Total Bilirubin = ULN for patients in group 3 and = 2.0 times ULN for patients in groups 1 and 2 - Hemoglobin = 9.0 g/dL - Creatinine = 1.5 times ULN or creatinine clearance = 60 mL/min - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception for the duration of study treatment - Willing to provide blood samples for mandatory translational studies Exclusion criteria - Known allergy to irinotecan hydrochloride-related agents (e.g., topotecan), 5-fluorouracil, and/or leucovorin calcium - Active or uncontrolled infection - Evidence of serious intercurrent illness (e.g., unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) PRIOR CONCURRENT THERAPY: - Recovered from all toxicities - More than 4 weeks since prior major surgery - More than 2 weeks since completion of prior radiotherapy - No prior radiotherapy to > 25% of bone marrow - More than 2 week since prior cytotoxic chemotherapy, biologic therapy, or immunotherapy - No concurrent sargramostim (GM-CSF) |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose of genotype-based dosing of FOLFIRI with or without monoclonal antibody therapy | |||
Secondary | Response rate of genotype-based dosing in the subset of patients that has colorectal cancer |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |